Bayer Receives FDA Approval for Jivi (antihemophilic factor (recombinant), PEGylated-aucl) for Prophylactic Treatment of Hemophilia A

WHIPPANY, N.J., Aug. 30, 2018 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Jivi ® (BAY94-9027, antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of...

https://www.drugs.com/newdrugs/bayer-receives-fda-approval-jivi-antihemophilic-f...

Source: Drugs.com - New Drug Approvals - August 30, 2018 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Haemophilia | Hemophilia